USP22 was initially identified in microarray screens as a member of an 11-gene “death-from cancer” signature that can be used to predict tumor recurrence, metastasis, highly aggressive tumors, and poor prognosis for people with one of several types of cancers135,136. This evidence concerns the gene USP22 and neoplasm.